Cryotherapy and cryoimmunotherapy for pancreatic cancer

Yong Tang, Zhanna Yuan, Fenghua Liu, Jihui Hao

    Research output: Contribution to journalReview article

    2 Scopus citations


    The prognosis of pancreatic cancer patients is extremely poor, and the cure effects of various treatments are not quite satisfactory. Cryosurgery has achieved good results in the treatment of various solid tumors. However, little pancreatic cancer data have been reported. In vitro and In vitro experiments show that cryosurgery destroys tumor cells and has good security. Clinical studies have indicated that in the freezing-based comprehensive treatment of advanced pancreatic cancer, the median survival ranges from 13.4 months to 16 months, and the 1-year survival rate is between 57.5% and 63.6%. These figures indicate that cryotherapy is safe for patients. Its major complications include delayed gastric emptying (0% to 40%), pancreatic leakage (0% to 6%), and biliary leakage (0% to 6.8%). Most importantly, after cryoablation, the tumor releases large amounts of antigens in the form of cell necrosis byproducts and debris, which induce freeze immunity and then inhibit tumor growth and metastasis. Most importantly, local cryoablation combined with systemic immunotherapy could provide new advanced cancer treatment techniques and strategies.

    Original languageEnglish (US)
    Pages (from-to)997-999
    Number of pages3
    JournalChinese Journal of Clinical Oncology
    Issue number14
    StatePublished - Jul 30 2012



    • Cryoablation
    • Cryoimmunotherapy
    • Effectiveness
    • Pancreatic cancer
    • Security

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this